OTCQB:IPIX - OTCQB:PPCB - OTCQB:VKIN - OTCQX:CNXXF - OTCQX:ZEST - 24/7 Market News

Venture Breakfast Bits, by 24/7 Market News

2019-01-02T09:48:33+00:00 Jan. 2, 2019 9:47AM EST|

Venture Market News for January 2, 2019

  • Viking Closes ~ $90 Million Acquisition and Financing Transaction; Significantly Expands Portfolio of Producing Oil & Gas Assets in Texas and Louisiana

HOUSTON, TX, Jan. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Viking Energy Group, Inc. (“Viking”) (OTCQB: VKIN) is pleased to announce that it has acquired  producing oil and gas assets in Texas and Louisiana, and increased its overall proven oil and gas reserves by approximately 10,500,000 BOE in connection with the acquisition.

Full press release

  • Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate

BEVERLY, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, reported today that the U.S. Patent & Trademark Office recently announced the awarding of a new patent allocated to Brilacidin.

Full press release

  • Ecoark Holdings, Inc. Establishes $10 Million Credit Facility to Accelerate Growth

ROGERS, Ark., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Ecoark Holdings, Inc. (“Ecoark”), to be renamed Zest Technologies, Inc., (OTCQX: ZEST), an AgTech company modernizing the post-harvest fresh food supply chain, has established a revolving credit facility with Trend Discovery SPV I, LLC for up to $10 million that will help fund the company’s continued growth and market development. Ecoark’s wholly-owned subsidiary, Zest Labs, continues to see a high-level of interest in its freshness management and operational efficiency solutions from national growers and leading retailers across North America.

Full press release

  • Propanc Biopharma Commences Drug Discovery Research Collaboration

Propanc Biopharma, Inc. (OTCQB: PPCB) ("Propanc"), a clinical stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced that a cooperation agreement has been entered into between the University of Jaén and Propanc to commence the POP1 joint drug discovery program to be co-funded by both parties. The agreement coincides with the appointment of research scientist, Mr. Aitor González, to lead the drug discovery and research activities over the next 3 to 4 years. The objective of the program is to identify and develop suitable backup compounds to Propanc’s lead product candidate, PRP.

Full press release

  • Cannex Reports Q2 Financial Results

January 2, 2019- OTC Disclosure & News Service- Vancouver, BC, Canada —This release includes additional documents. Select the link(s) below to view.

CANNEX NR - Cannex Reports Q2 Financial Results (Jan 2 2019).pdf

Full press release

Connect with 24/7 Market News on social media

https://twitter.com/247MarketNewsHQ

https://www.facebook.com/247MarketNewsHQ/

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information.  24/7 MN provides comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable. 24/7MN makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice.   24/7MN and/or its affiliates are not responsible for any gains or losses that result from the opinions expressed and are not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.

For further information on 24/7 Market News, please go to www.247marketnews.com 

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan," or "planned," "will," or "should," "expected," "anticipates," "draft," "eventually," or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and 24/7MN undertakes no obligation to update such statements

CONTACT:

24/7 Market News

Editor@247marketnews.comTop of Form

Send this to a friend

Hi, this may be interesting you: Kraig Biocraft Laboratories’ New R&D Facility Extends Its Competitive Advantages and Prepares for Large Scale Production! This is the link: https://www.247marketnews.com/kraig-biocraft-laboratories-new-rd-facility-extends-its-competitive-advantages-and-prepares-for-large-scale-production/